Status
Completed
Phase
Not applicable
Enrollment
851
Locations
1
Results
Not posted
Publications
7
Study summary
This is a study aiming to investigate a possible correlation between the parameters affecting the physicians' therapeutic choice with the patients' overall adherence to osteoporosis treatment. Secondary end-points include correlation between the parameters affecting the physicians' therapeutic choice and the patients' quality of life as well as the evaluation of the whole osteoporosis treatment approach of orthopedic surgeons in Greece (diagnostic means, use of diagnostic and treatment guidelines, methodology of follow - up).
The study will include 100 orthopedic surgeons from the private sector working in private offices. The selection of this group of physicians resides on the fact that orthopedic surgeons working in private offices hold more than 60% of osteoporosis prescriptions in Greece. Each physician will fill once a questionnaire regarding the parameters affecting his/her choice of osteoporosis treatment before entering any patient in the study. Following the completion of the questionnaire every physician will recruit up to 10 patients in the study who are eligible for osteoanabolic treatment (teriparatide) according to standard medical practice and the Greek osteoporosis treatment guidelines. Each patient will receive teriparatide up to 24 months while he/she will fill the Greek EQ5D questionnaire on months: 0,12,24 or at early discontinuation. Adherence to treatment will be evaluated at the same time points as well as on monthly telephone interviews. Both the adherence to treatment and the possible alteration of patients' quality of life (evaluated through the EQ5D questionnaire) during the study will be correlated with the parameters affecting the initial therapeutic decision of the physician
Interventions
DRUG
The study will include patients from pre-defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
Timeline
First posted
Jun 16, 2015
Study start
May 2015
Primary completion
Jun 30, 2018
Study completion
Dec 15, 2018
Results posted
Not reported
Registry updated
Jan 10, 2019
Outcomes
Adherence to osteoporosis treatment assessed by medication possession ratio (MPR)
Time frame · 2 years
Adherence to osteoporosis treatment assessed by medication possession ratio Adherence to osteoporosis treatment assessed by medication possession ratio (MPR) and correlation with the parameters affecting the physicians' therapeutic choices
Quality of life assessed by EQ5D questionnaire
Time frame · 2 years
Quality of life assessed by EQ5D questionnaire and correlation with the parameters affecting the physicians' therapeutic choice
Eligibility
Inclusion Criteria: * Female patients with postmenopausal osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study. * Male patients ≥ 50 years old with idiopathic osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study. * Male and female patients with steroid-induced osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study. Exclusion Criteria: * Prior use of teriparatide or PTH(1-84) * Hypersensitivity to teriparatide regimen. * Pregnancy and lactation. * Hypercalcamia. * Renal deficiency (eGFR \< 30 ml/min). * Other bone metabolic diseases (including hyperparathyroidism and Paget's disease) except primary osteoporosis or steroid induced osteoporosis . * Uninterpretable increases of alkaline phosphatase (ALP) * Prior skeletal radiotherapy. * Skeletal malignancies or bone metastases
Study locations
Greece. Showing up to 24 locations stored in the fast local snapshot.
251 Hellenic Air Force & VA General Hospital
Athens, Attica, Greece
Publications
Related trials
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
Syneos Health · Healthy Volunteers
Phase 1
Recruiting
48
2026-07
University of Edinburgh · Osteogenesis Imperfecta
Phase 4
Completed
350
2026-06
Sheffield Teaching Hospitals NHS Foundation Trust · Osteoporosis
Phase 4
Completed
19
2026-05
The University of Hong Kong · Osteoporosis · Fusion of Spine, Lumbar Region
Not applicable
Active, not recruiting
192
2026-05
Madhumathi Rao · Age-Related Osteoporosis
Phase 4
Active, not recruiting
60
2026-05
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 2
Recruiting
200
2026-05
University Health Network, Toronto · Osteoporosis
Not applicable
Active, not recruiting
100
2026-05
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.